Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.
Thanks!

Click here for a guide on disabling your adblocker.

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

UK grower receives approval to import cannabis flower into Israel

The Government of Israel has granted a license for cannabis flower grown at Ananda’s subsidiary, DJT Plants to be imported into Israel. The license is held by Cannasoul Analytics, the research company which will be analyzing DJT Plants’ cannabis flower.

"The purpose of obtaining an import license at this early stage is to ensure that DJT Plants has a clear understanding of all requirements for moving cannabis flower, a controlled drug under the UK Government’s Misuse of Drugs Act 1971, from the UK into Israel," the Ananda team explains. "The import license was awarded by Israel’s Department of Pharmaceutical Import and Narcotics at the Ministry of Health, and by the Ministry of Agriculture and Rural Development Plant Protection and Inspection Services. Appropriate licenses will be sought under the relevant UK legislation allowing the export of cannabis flowers from the UK nearer to the time of export."

In April 2020, Ananda announced that it would be collaborating with Professor Dedi Meiri, the leading global medical cannabis researcher at The Technion in Israel, to carry out a detailed molecular analysis of the strains of cannabis which Ananda proposes to grow and stabilize at DJT Plants.

As part of Ananda’s research plan to stabilize 65 strains of medical cannabis and conduct field trials, future cannabis plant material grown by DJT Plants will be sent to Cannasoul Analytics, an Israel-based commercial research company formed by Professor Dedi Meiri, for analysis of cannabinoid, terpene and flavonoid profiles. It is the view of the Directors of Ananda that Israel continues to be at the forefront of global medical cannabis research and that Israel’s experts have the greatest depth of understanding of the cannabis plant at the molecular level.

Ananda’s ultimate ambition is for DJT Plants to transition to commercial growing of medical cannabis. The Board remains encouraged by progress.

Preparation of documentation continues for the acquisition of the 50% of DJT Group Limited not already owned by Ananda. This work includes the drafting of a range of supporting agreements. Further detail on the proposed acquisition is detailed in the Company’s announcement of 8 June, 2021.

For more information:
Ananda Developments
www.anandadevelopments.com 

Publication date: